COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

被引：0
|
作者：
Woods, B. [1 ]
Thompson, J. [1 ]
Barcena, L. [1 ]
Liu, Y. [2 ]
Huang, H. [2 ]
Martinez, C. [3 ]
机构：
[1] Oxford Outcomes, Oxford, England
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Inst Hematol & Oncol, Barcelona, Spain
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1728
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A509 / A509
页数：1
相关论文
共 50 条
  • [31] Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naive Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study
    Viviani, Simonetta
    Dalto, Serena
    Matteucci, Paola
    Di Nicola, Massimo
    Guidetti, Anna
    Devizzi, Liliana
    Magni, Michele
    Dodero, Anna
    Farina, Lucia
    Spina, Francesco
    Gianni, Alessandro M.
    Corradini, Paolo
    BLOOD, 2014, 124 (21)
  • [32] Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma
    Massa, Hanne
    Massaro, Fulvio
    Maerevoet, Marie
    BIOMEDICINES, 2025, 13 (02)
  • [33] Brentuximab Vedotin Strategies for Relapsed Or Refractory Hodgkin's Lymphoma And Hematopoietic Stem Cell Transplantation
    Garzon-Velasquez, Katheryn
    Lizeth Acosta-Maldonado, Brenda
    Manuel Valero-Saldana, Luis
    Moreira-Ponce, Carolina
    Marcela Aguado-Vazquez, Tania
    Maylen Rivera-Fong, Liliana
    Rivas-Vera, Silvia
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 252 - 253
  • [34] A Simple Model for Predicting Post-Autologous Stem Cell Transplantation Outcome in Patients with Relapsed/Primary Refractory Hodgkin Lymphoma
    Dann, Eldad J.
    Sobol, Shani
    Mashiach, Tania
    Katz, Tamar
    Zuckerman, Tsila
    BLOOD, 2018, 132
  • [35] ALLOGENEIC STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER EXPERIENCE
    Festuccia, M.
    Busca, A.
    Zallio, F.
    Sorasio, R.
    Brunello, L.
    Maffini, E.
    Dellacasa, C.
    Passera, R.
    Iovino, G.
    Aydin, S.
    Mordini, N.
    Pini, M.
    Boccadoro, M.
    Bruno, B.
    Giaccone, L.
    HAEMATOLOGICA, 2016, 101 : 320 - 320
  • [36] REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA POST AUTOLOGOUS STEM-CELL TRANSPLANTATION
    Zagadailov, E. A.
    Corman, S.
    Hagan, M.
    Chirikov, V.
    Johnson, C.
    Macahilig, C.
    Sea, B.
    Dalal, M. R.
    Broeckelmann, P. J.
    Illidge, T.
    HAEMATOLOGICA, 2016, 101 : 51 - 51
  • [37] FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant For Relapsed and Refractory Hodgkin Lymphoma
    Moskowitz, Alison
    Schoder, Heiko
    Gerecitano, John F.
    Hamlin, Paul
    Horwitz, Steven M.
    Matasar, Matthew J.
    Keskinyan, Vahakn S.
    McCall, Susan
    Noy, Ariela
    Palomba, M. Lia
    Portlock, Carol S.
    Straus, David J.
    Yahalom, Joachim
    Younes, Anas
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    BLOOD, 2013, 122 (21)
  • [38] Real-world outcomes of brentuximab vedotin maintenance after autologous stem cell transplant in relapsed/refractory classical Hodgkin lymphoma: Is less enough?
    Wagner, Charlotte Burton
    Ermann, Daniel Arthur
    Boucher, Kenneth M.
    Nedved, Adrienne
    Micallef, Ivana N. M.
    Hatic, Haris
    Goyal, Gaurav
    Hickey, Erin
    Fegley, Amanda
    Samuels, Courtney
    Kamdar, Manali K.
    Aqeel, Sheeba Habeeb Ba
    Torka, Pallawi
    MacDougall, Kira
    Borogovac, Azra
    Rajeeve, Sridevi
    Fedak, Kalub
    Travers, Elizabeth
    Shah, Harsh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed by Autologous Stem Cell Transplant for Relapsed and Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (02) : 7 - 7
  • [40] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
    Damlaj, Moussab
    Abuelgasim, Khadega A.
    Alhejazi, Ayman
    Alahmari, Bader
    Alaskar, Ahmed
    Alzahrani, Mohsen
    BONE MARROW TRANSPLANTATION, 2020, 55 (12) : 2322 - 2325
12345